Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating income | — | — | — | — | -$37.4M | -$113M | -$15.5M | -$14.3M | -$13.2M |
| Net income | -$15.2M | -$15.5M | -$28.1M | -$53.5M | -$37.1M | -$113M | -$14.3M | -$13.0M | -$12.6M |
| EPS (diluted) | -$13.17 | -$13.45 | -$4.67 | -$50.61 | -$34.88 | -$67.99 | -$3.95 | -$2.35 | -$1.93 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.0M | -$15.3M | -$26.7M | -$41.8M | -$37.7M | -$25.0M | -$12.2M | -$13.6M | -$12.9M |
| Capital expenditures | — | $3.70K | $30.9K | $25.7K | — | — | $93.1K | $15.5K | — |
| Free cash flow | — | -$15.3M | -$26.7M | -$41.8M | — | — | -$12.3M | -$13.6M | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.4M | $65.7M | $130M | $89.0M | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M |
| Total assets | — | $66.0M | $134M | $92.8M | $56.8M | $30.2M | $22.7M | $24.0M | $15.9M |
| Total liabilities | — | $4.87M | $9.36M | $15.4M | $7.32M | $3.20M | — | — | — |
| Shareholders' equity | -$35.8M | -$51.4M | $124M | $77.4M | $49.5M | $25.6M | $17.0M | $19.3M | $12.4M |
| Retained earnings | — | -$62.5M | -$90.5M | -$144M | -$181M | -$294M | -$308M | -$321M | -$334M |
| Shares (wtd avg diluted) | — | 1.16M | 6.00M | 1.06M | 1.06M | 1.66M | 3.62M | 5.51M | 6.54M |
Every figure is extracted from Aprea Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.